Tornado Licenses 82 Rapamycin Derivatives for Trials
D
Dr. Joan Mannick on InsideTracker's Channel
Anti-AgingMedical
Story of claim
Tornado Therapeutics has secured 82 novel rapamycin derivatives from Novartis to explore safer, more effective mTOR inhibitors aimed at extending human health span.
- Goal: Extend human health span through safer and more effective mTOR inhibitors.
- Proof: Rapamycin derivatives may help in developing therapies that extend the human health span.
- Nuances:
- Involvement of multiple stakeholders in the development and testing
- Encouragement to participate in clinical trials for conclusive results
- Impact on Life: These trials may lead to breakthroughs in aging therapies, potentially improving quality of life as people age.
Investments
- Price:
- Time:
- Effort:
Risks
Potential risks involved in trial participation; other companies exploring similar derivatives.
Get Started 🚀
- Consider enrolling in clinical trials for rapamycin derivatives
- Stay informed about developments in mTOR inhibitor research
- Consult with healthcare professionals before considering participation
Brogevity AI can make mistakes. Check important info.